ZIVO vs. MDWD, CHRS, CRBP, CGEN, GNLX, SAVA, BIOA, FTLF, PLX, and ACTU
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include MediWound (MDWD), Coherus Oncology (CHRS), Corbus Pharmaceuticals (CRBP), Compugen (CGEN), Genelux (GNLX), Cassava Sciences (SAVA), BioAge Labs (BIOA), FitLife Brands (FTLF), Protalix BioTherapeutics (PLX), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
ZIVO Bioscience (NASDAQ:ZIVO) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.
ZIVO Bioscience has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
ZIVO Bioscience has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. ZIVO Bioscience's average media sentiment score of 0.67 beat MediWound's score of 0.05 indicating that ZIVO Bioscience is being referred to more favorably in the media.
MediWound has a consensus price target of $32.25, suggesting a potential upside of 74.80%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than ZIVO Bioscience.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
ZIVO Bioscience has a net margin of 0.00% compared to MediWound's net margin of -142.18%. ZIVO Bioscience's return on equity of 0.00% beat MediWound's return on equity.
Summary
ZIVO Bioscience beats MediWound on 8 of the 15 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 10/22/2025 by MarketBeat.com Staff
